- Email:
- Phone:
- Add:
Zebrafish High-Throughput Drug Screening Service
The pharmaceutical industry has adopted Zebrafish High-Throughput Screening (ZHTS) as an essential preclinical approach, rapidly and efficiently providing whole-organism data to bridge the predictive gap between in vitro tests and costly mammalian studies. This strategy significantly lowers drug attrition rates by enabling physiologically relevant hit identification and validation. BioVenic focuses on developing highly relevant disease models using advanced genetic engineering techniques, including precise gene editing for targeted gene disruption and the creation of stable transgenic lines that express fluorescent reporters in specific tissues, ensuring unmatched assay relevance for every client screen.
The rise of phenotypic screening demands model organisms that capture the complexity of human pathology. The zebrafish, Danio rerio, excels here, possessing over 70% genetic homology with humans and conserved orthologs for most human disease-related genes. Its rapid, external development and larval optical transparency allow for non-invasive, real-time observation of complex physiological processes, such as cardiac function, neurodevelopment, and angiogenesis. Currently, ZHTS is recognized globally for its capacity to test thousands of compounds quickly in a vertebrate context, offering superior predictive validity over cellular assays. Its immense potential lies in the ability to identify multi-mechanism therapeutic leads for complex, polygenic diseases previously intractable to single-target approaches, accelerating the path to clinical translation.
Fig.1 Workflow of screening the number of hematopoietic stem cells in the tail of zebrafish embryos.1,2
Zebrafish HTS offers unparalleled integration of physiological complexity and scalability, empowering drug discovery teams to move beyond basic cellular data and focus on actionable leads.
Phenotypic Discovery and Mechanism
ZHTS is a phenotype-first approach, enabling the discovery of drug candidates that modulate entire biological pathways rather than being restricted to a single target. This approach is crucial for identifying novel therapeutic leads, especially for diseases with undefined or polygenic etiologies, by screening against disease-relevant phenotypes.
Simultaneous Safety and Efficacy
The innate optical transparency of the larvae allows for the concurrent, early-stage assessment of drug efficacy and multi-organ toxicity—including developmental toxicity, cardiotoxicity, and neurotoxicity—in the same animal. This dual-purpose data collection significantly de-risks hit compounds and streamlines subsequent preclinical development.
Rapid In Vivo Validation
The high-throughput nature and short life cycle of the larval stage facilitate rapid validation of hit compounds in a living vertebrate environment. This rapid feedback loop accelerates lead optimization and ensures only the most promising, in vivo-validated candidates progress to costly mammalian and clinical trials.
Oncology and Xenograft Modeling
Zebrafish serve as rapid, cost-effective patient-derived xenograft (PDX) models. We can non-invasively monitor tumor growth, metastasis, and therapeutic response in real-time within the transparent host, providing crucial insights for personalized medicine and novel chemotherapeutic screening.
BioVenic provides an end-to-end, one-stop service for Zebrafish High-Throughput Drug Screening, seamlessly integrating model creation, screening, and validation into a unified pipeline. Our comprehensive services ensure maximum data integrity and efficiency for your project. Our integrated ZHTS pipeline covers the entire preclinical discovery workflow:
| Service | Process and Related Technology |
| Targeted Disease Modeling | Advanced genetic engineering and custom assay optimization to define precise, quantifiable endpoints relevant to your therapeutic area. |
| High-Throughput Drug Screening (HTS) | Employing robotic liquid handling for precise compound delivery into multi-well plates, coupled with advanced High-Content Imaging (HCI) systems to rapidly acquire thousands of high-resolution images. |
| Drug Toxicity Screening & Efficacy Verification | Simultaneous, early-stage assessment of efficacy alongside toxicity (developmental, cardio-, neurotoxicity) using HCI and AI-Driven Data Analysis for robust hit compound de-risking. |
| Validation and Research on Drug Molecular Mechanisms | Provides secondary screens, detailed dose-response studies, and molecular biology support (including drug molecular structure optimization services) to confirm activity and deliver initial mechanistic insights into the compound's mode of action. |
Professional Team
Customized Services
Innovative Technology
Efficient Services
Choosing BioVenic means partnering with expert biological specialization and a commitment to operational excellence. Our integrated platform, combining custom model generation with automated, AI-powered screening, maximizes the predictive power and speed of your discovery efforts. We prioritize robust data integrity and translational fidelity, guaranteeing results that truly inform your pipeline decisions. Contact us and submit your requirements to receive a detailed quote to accelerate your drug discovery with BioVenic's definitive ZHTS platform.
Reference
Our products and services are for research use only and cannot be used for any clinical purposes.